SCHEMBL25835446

SCHEMBL25835446

NCCOCCC(=O)NCCOCCNC(=O)CCCCCCCCCCCCCCCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.54
HDAC2 Q92769 3/20 0.54
LMNA P02545 3/20 0.54
HDAC3 O15379 2/20 0.54
HDAC10 Q969S8 2/20 0.54
HDAC11 Q96DB2 2/20 0.54
HDAC8 Q9BY41 2/20 0.54
HDAC6 Q9UBN7 2/20 0.54
NCOR2 Q9Y618 2/20 0.54
TSHR P16473 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
F13A1 P00488 1/20 0.53
ALOX5 P09917 1/20 0.52
TAAR1 Q96RJ0 1/20 0.52
TRPV1 Q8NER1 2/20 0.50
KDM4E B2RXH2 1/20 0.49
PKM P14618 1/20 0.49
HDAC4 P56524 1/20 0.49
HDAC9 Q9UKV0 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25293407 0.91 L3MBTL1 (0.57) HDAC1HDAC2LMNAHDAC3HDAC10
SCHEMBL21633621 0.91 L3MBTL1 (0.57) HDAC1HDAC2LMNAHDAC3HDAC10
SCHEMBL25254833 0.91 L3MBTL1 (0.57) HDAC1HDAC2LMNAHDAC3HDAC10
SCHEMBL30683377 0.84 HDAC1 (0.66) HDAC1HDAC2LMNAHDAC3HDAC10
SCHEMBL25835445 0.82 SIGMAR1 (0.53) HDAC1HDAC2LMNAHDAC3HDAC10
SCHEMBL26393874 0.80 L3MBTL1 (0.60) HDAC1HDAC2LMNAHDAC3HDAC10
SCHEMBL25287870 0.80 L3MBTL1 (0.60) HDAC1HDAC2LMNAHDAC3HDAC10
SCHEMBL29994442 0.80 LMNA (0.51) HDAC1HDAC2LMNAHDAC3HDAC10
SCHEMBL31235810 0.79 SMN1; SMN2 (0.56) LMNAL3MBTL1TAAR1KDM4E
SCHEMBL22590176 0.79 ALB (0.50) LMNAL3MBTL1TAAR1TRPV1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 US disclosed
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS CPT1B, MUSK, MYLK2 HDAC1 1399/4885HDAC2 1672/4885LMNA 1652/4885
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF MUSK, MYLK2, TNNC1 HDAC1 1456/4885HDAC2 1552/4885LMNA 1041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.